Projects per year
Personal profile
Biography
Dr. Donia Moujalled completed her PhD in 2012 at The Walter and Eliza Hall Institute of Medical Research in the Cell Death and Cell Signaling division, led by Prof. David Vaux. During her PhD, Dr. Moujalled examined the role of receptor interacting protein kinases in cell death induced by tumour necrosis factor receptor 1. She continued to work as a post-doctoral researcher in Prof. Vaux's lab 2012- 2013, recieving funding from The Cancer Austalia Foundation, to characterise RIPK3 and MLKL in necroptosis signaling induced by TNF.
In 2014, she moved to the Austrlian Centre for Blood Diseases, Monash University based at The Alfred Hospital. She joined the Leukemia Research Group, led by A/Prof. Andrew Wei. Her research focus is on developing in vivo pre-clinical models to examine BH3 mimetic compounds targeting pro-survival proteins BCL-2 and MCL1 in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia.
External positions
Honorary, The Alfred Hospital
2014 → …Research area keywords
- Acute myeloid leukaemia
- Acute lymphoblastic leukaemia
- apoptosis
- BH3 mimetics
- BCL-2
- MCL1
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2018 2020
- 1 Active
Research Output 2010 2019
Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T. C., Tiong, I. S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E., Colland, F. & 7 others, , 1 Apr 2019, In : Leukemia. 33, a, p. 905-917 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., Cardozo, M., Houze, J., Li, Y., Lucas, B., Paras, N. A., Wang, X., Taygerly, J. P., Vimolratana, M., Zancanella, M., Zhu, L. & 18 others, , 1 Dec 2018, In : Cancer Discovery. 8, 12, p. 1582-1597 16 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Teh, T. C., Nguyen, N. Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A., Cummins, K., Lackovic, K., Blombery, P., Thompson, E., Ekert, P. G., Lessene, G., Glaser, S. P., Huang, D. C. S., Roberts, A. W., Guthridge, M. A. & Wei, A. H., 1 Feb 2018, In : Leukemia. 32, 2, p. 303-312 10 p.Research output: Contribution to journal › Article › Research › peer-review
TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway
Moujalled, D., Grubman, A., Acevedo, K., Yang, S., Ke, Y. D., Moujalled, D. M., Duncan, C., Caragounis, A., Perera, N. D., Turner, B. J., Prudencio, M., Petrucelli, L., Blair, I., Ittner, L. M., Crouch, P. J., Liddell, J. R. & White, A. R., 1 May 2017, In : Human Molecular Genetics. 26, 9, p. 1732-1746 15 p., ddx093.Research output: Contribution to journal › Article › Research › peer-review
Correction: Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics (Cancer Cell (2016) 30(3) (499–500) (S1535610816000350) (10.1016/j.ccell.2016.01.006))
Lalaoui, N., Hänggi, K., Brumatti, G., Chau, D., Nguyen, N. Y. N., Vasilikos, L., Spilgies, L. M., Heckmann, D. A., Ma, C., Ghisi, M., Salmon, J. M., Matthews, G. M., de Valle, E., Moujalled, D. M., Menon, M. B., Spall, S. K., Glaser, S. P., Richmond, J., Lock, R. B., Condon, S. M. & 10 others, , 12 Sep 2016, In : Cancer Cell. 30, 3, p. 499-500 2 p.Research output: Contribution to journal › Comment / Debate › Other › peer-review